A pharma giant expresses interest in a Stamford biotech company after striking a deal worth up to $1.3 billion for a New ...

Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA stock a buy?

Also in Europe, officials signed off on CSL and Arcturus Therapeutics' self-amplifying mRNA COVID ... (PAH) drug, which also goes by the name sotatercept, was originally picked up via Merck ...

The pharmaceutical industry’s biggest lobbying group is scheduled to meet with President Donald Trump on Thursday, according ...

The rise of misinformation online has helped fringe health ideas go mainstream and eased RFK Jr.'s path to confirmation as ...

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

The discovery of this hormone paved the way for Ozempic, making the Gila monster an enormously profitable gift to modern ...

Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...

Orders for Merck & Co's oral antiviral for COVID-19 helped to swell the ... but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy Keytruda ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...